论文部分内容阅读
目的观察鼻咽癌人源抗独特型单链抗体G22ScFv在小鼠体内诱导的免疫应答,探讨其作为鼻咽癌疫苗的可能性。方法在大肠杆菌中诱导表达G22ScFv并进行纯化,以纯化的G22ScFv免疫BALB/c小鼠,采用间接ELISA及竞争抑制ELISA检测免疫小鼠特异性体液免疫应答水平;流式细胞术检测免疫小鼠脾T淋巴细胞表型的变化。结果纯化的融合蛋白纯度达95%以上,且具有良好的反应原性。经ELISA检测,G22ScFv免疫后,小鼠产生了Ab3,且小鼠脾脏CD4+、CD8+T淋巴细胞数量升高。结论G22ScFv可诱导机体产生体液免疫和细胞免疫应答,为鼻咽癌人源抗独特型抗体疫苗的临床应用奠定了基础。
Objective To observe the immune response of nasopharyngeal carcinoma human anti-idiotypic single chain antibody G22ScFv in mice and to explore its potential as a vaccine for nasopharyngeal carcinoma. Methods G22ScFv was induced and purified in Escherichia coli. BALB / c mice were immunized with purified G22ScFv. The specific humoral immune responses of the mice were detected by indirect ELISA and competitive inhibition ELISA. Flow cytometry T lymphocyte phenotype changes. Results The purity of the purified fusion protein was more than 95%, and it had good reaction. After the G22ScFv immunization, the mice produced Ab3 by ELISA, and the number of spleen CD4 + and CD8 + T lymphocytes in mice increased. Conclusion G22ScFv can induce humoral and cellular immune response in human body and lay a foundation for the clinical application of human anti-idiotypic antibody vaccine for nasopharyngeal carcinoma.